Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVLITE vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Emergency contraception,Contraception (as part of combination oral contraceptives or intrauterine system),Off-label: menstrual disorders, endometriosis
Prevention of pregnancy
One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life: 21-28 hours; clinical context: permits once-daily dosing
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic via CYP3A4; reduced to inactive metabolites; excreted in urine and feces.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: ~50% (30% as unchanged drug, 20% as metabolites); Fecal: ~40%; Biliary: minor
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Levonorgestrel: ~99% bound to sex hormone-binding globulin (SHBG) and albumin; Ethinyl estradiol: ~98% bound to albumin
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Levonorgestrel: 1.8 L/kg; Ethinyl estradiol: 2.5 L/kg; clinical meaning: extensive tissue distribution
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: ~100% for both levonorgestrel and ethinyl estradiol (high bioavailability due to minimal first-pass metabolism)
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use with caution.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in severe hepatic disease (Child-Pugh Class C). For mild to moderate impairment (Child-Pugh A/B), use with caution and monitor liver function.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use in postmenarchal pediatric patients; safety and efficacy not established in prepubertal children.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women; no specific geriatric dosing studies available.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events. Women over 35 who smoke should not use combination hormonal contraceptives.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders,Hepatic disease,Hypertension,Diabetes,Gallbladder disease,Depression,Ectopic pregnancy risk (emergency contraception),Reduced efficacy with CYP3A4 inducers
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Severe hepatic disease,Known or suspected breast cancer,History of thromboembolic disorders,Hypersensitivity to levonorgestrel
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No known significant food interactions. Grapefruit and grapefruit juice do not interact with ethinyl estradiol or levonorgestrel. However, a high-fat meal may increase absorption of some oral contraceptives; consistency in taking with or without food is recommended.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
FDA Pregnancy Category X. Ethinyl estradiol and levonorgestrel are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular defects and limb reduction defects from first-trimester exposure. Second and third trimester exposure may be associated with genitourinary abnormalities and masculinization of female fetuses.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in breast milk in small amounts. Ethinyl estradiol concentration in milk ~0.02-0.1 ng/m L; levonorgestrel M/P ratio ~0.35-1.0. No adverse effects reported at typical doses. May reduce milk production; use caution in lactating women, especially with high doses.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dose adjustment applicable as use is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, decreased binding protein) are irrelevant due to contraindication.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
LEVLITE is a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Use with caution in women with migraines with aura due to increased stroke risk. Smoking increases cardiovascular risk, especially in women over 35. Monitor blood pressure at baseline and periodically. Consider alternative contraception in women with uncontrolled hypertension or history of venous thromboembolism.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time each day.,If you miss a pill, follow the package instructions or consult your healthcare provider.,Do not smoke while taking this medication, as it increases the risk of blood clots and heart problems.,Use barrier contraception if you also take certain antibiotics or anticonvulsants.,Common side effects include nausea, headache, and breast tenderness, which often improve after a few months.,Seek immediate medical help for symptoms of a blood clot: leg pain/swelling, sudden chest pain, or trouble breathing.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVLITE vs ALYACEN 7/7/7, answered by our medical review team.
LEVLITE is a Oral Contraceptive that works by Levonorgestrel is a progestin that suppresses ovulation by inhibiting gonadotropin release (LH and FSH) and alters cervical mucus, endometrial thickness, and tubal motility.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVLITE and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVLITE is: One tablet (levonorgestrel 0.1 mg, ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVLITE and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVLITE is classified as Category C. FDA Pregnancy Category X. Ethinyl estradiol and levonorgestrel are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular defects and limb reduction defec. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.